Direct-acting antivirals failed to reduce the incidence of hepatocellular carcinoma occurrence in hepatitis C virus associated cirrhosis: A real-world study

Table 3 Factors of hepatocellular carcinoma occurrence in all patients with hepatitis C virus associated cirrhosis (n = 427)

Variables	Univariate			Multivariate
	HR	95%CI	P value	HR	95%CI	P value
DAA treated	0.478	0.245-0.933	0.03
Ages (yr)	1.052	1.019-1.087	0.002	1.089	1.033-1.147	0.002
Gender (M/F)	1.297	0.750-2.242	0.352
Cirrhosis (compensate/de)	2.312	1.271-4.207	0.006
nonspecific nodules (Y/N)	3.112	1.734-5.586	0
Child-Pugh (A/B/C)	2.184	1.416-3.367	0
Fatty liver	0.686	0.271-1.738	0.427
FIB-4	1.063	1.026-1.101	0.001
AFP (ng/mL)	0.994	0.981-1.008	0.419
AST (U/L)	1.005	0.999-1.010	0.126
ALB (g/L)	0.922	0.885-0.961	0
TIBL (μmol/L)	1.015	1.007-1.022	0
PT	1.23	1.083-1.398	0.001
PLT	0.992	0.986-0.997	0.005
LSM	1.038	1.018-1.058	0	1.043	1.022-1.065	0

HCC: Hepatocellular carcinoma; HR: Hazard ratio; DAA: Direct-acting antiviral agents; FIB-4: The Fibrosis-4 index; ALBI: The albumin-Bilirubin score; AFP: Alpha fetoprotein; AST: Aspartate aminotransferase; ALB: Albumin; TBIL: Total bilirubin; EOT: End of treatment; PLT: Platelet; PT: Prothrombin time; LSM: Liver stiffness measurement.